On Nov 08, major Wall Street analysts update their ratings for $Cytokinetics (CYTK.US)$, with price targets ranging from $70 to $120.
Morgan Stanley analyst Jeffrey Hung maintains with a hold rating, and maintains the target price at $70.
Barclays analyst Carter Gould maintains with a buy rating, and maintains the target price at $95.
Needham analyst Serge Belanger maintains with a buy rating, and maintains the target price at $72.
RBC Capital analyst Leonid Timashev initiates coverage with a buy rating, and sets the target price at $80.
Piper Sandler analyst Yasmeen Rahimi maintains with a buy rating, and maintains the target price at $107.
Furthermore, according to the comprehensive report, the opinions of $Cytokinetics (CYTK.US)$'s main analysts recently are as follows:
The significant decline in Cytokinetics' share value since the January peak suggests that the market may not be fully recognizing the potential $3.6 billion opportunity presented by aficamten, considering its convenience, safety, and efficacy in treating hypertrophic cardiomyopathy. Additionally, there is perceived upside from the company's pipeline, with projections that omecamtiv and CK-586 could generate a combined total of over $1.5 billion in long-term revenues.
Here are the latest investment ratings and price targets for $Cytokinetics (CYTK.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
